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Fatty liver is associated with 
blood pathways of inflammatory 
response, immune system 
activation and prothrombotic state 
in Young Finns Study
Tuukka Taipale1, Ilkka Seppälä  1, Emma Raitoharju1, Nina Mononen1, Leo-Pekka Lyytikäinen  1, 
Thomas Illig2,3, Melanie Waldenberger4, Markus Juonala5,6, Nina Hutri-Kähönen7, Niku Oksala1,8, 
Mika Kähönen9, Olli Raitakari10,11 & Terho Lehtimäki1
Fatty liver (FL) disease is the most common type of chronic liver disease. We hypothesized that liver’s 
response to the process where large droplets of triglyceride fat accumulate in liver cells is reflected 
also in gene pathway expression in blood. Peripheral blood genome wide gene expression analysis 
and ultrasonic imaging of liver were performed for 1,650 participants (316 individuals with FL and 
1,334 controls) of the Young Finns Study. Gene set enrichment analysis (GSEA) was performed for the 
expression data. Fourteen gene sets were upregulated (false discovery rate, FDR < 0.05) in subjects 
with FL. These pathways related to extracellular matrix (ECM) turnover, immune response regulation, 
prothrombotic state and neural tissues. After adjustment for known risk factors and biomarkers of FL, 
we found i) integrin A4B1 signaling, ii) leukocyte transendothelial migration, iii) CD40/CD40L and iv) 
netrin-1 signaling pathways to be upregulated in individuals with FL (nominal p < 0.05). From these all 
but not ii) remained significantly upregulated when analyzing only subjects without history of heavy 
alcohol use. In conclusion, FL was associated with blood gene sets of ECM turnover, inflammatory 
response, immune system activation and prothrombotic state. These may form a systemic link between 
FL and the development of cardiovascular diseases.
The fatty liver disease (FLD) is a common liver disorder in western industrialized countries and an emerging 
problem in the Asia-Pacific region. FLD is often associated excessive alcohol consumption (alcoholic fatty liver 
disease, AFLD) or obesity with or without insulin resistance i.e., non-alcoholic fatty liver disease (NAFLD)1,2. 
Currently NAFLD is the most common cause of chronic liver disease3, affecting up to one third of US population4 
and 70–90% of the obese and diabetics5. The main characteristic of FLD irrespective of the cause is the accu-
mulation of triglyceride lipid droplets (>5% of liver weight) in liver cells1–3,6. The increased level of intrahepatic 
fatty acids may lead into cell damage and inflammation and provide a source of oxidative stress promoting fatty 
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liver progression from steatosis to steatohepatitis and subsequently to cirrhosis or ultimately to hepatocellular 
carcinoma2,6.
The primary causes leading to hepatocellular lipid accumulation are not yet well understood, but they are 
thought to include alterations in the hepatic lipid uptake, synthesis, degradation and secretion. Also, its meta-
bolic, systemic and clinical consequences are still incompletely understood6,7. For example, clinically patients 
who eventually develop progressive liver cirrhosis or liver failure cannot be differentiated from those who do not. 
Immune system activation and inflammation are key players in the pathogenesis of FLD8–11. NAFLD is consid-
ered as an early mediator of systemic disease12. Innate immune system is deeply involved in pathophysiological 
events of fatty liver by following mechanisms: TLR-4 dependent signaling activates the Kupffer cells, complement 
pathway activation, balancing the cytokine network towards pro-inflammatory mediators, alternation in natural 
killer (NK) and NK T cell number and activity, and activation of the adaptive immune system leading to severe 
liver disease8. The involvement of adaptive immunity in the evolution of fatty liver and its complications is under 
research. Present evidence suggests that adaptive immunity contributes not only to the maintenance of fatty liver 
but also to the progression and comorbidities of it8,13. Immuno-inflammatory mechanisms are present in several 
comorbidities related with FLD, including obesity, type 2 diabetes, chronic kidney disease, metabolic syndrome, 
and cardiovascular diseases5,12. However, the actual pathophysiological mechanisms connecting these states are 
not well known.
The purpose of the present study was to reveal alterations in gene pathways related to FLD in a population 
based study cohort. We hypothesized that accumulated fatty acids and large droplets of triglycerides in liver cells 
trigger an inflammatory response in liver, which is visible via differential immuno-inflammatory gene pathway 
expression in blood. Understanding the pathogenic mechanisms of FLD and its metabolic and systemic conse-
quences will give us new insight to the disease process and comorbidities of FLD.
Material and Methods
Subjects. The Cardiovascular Risk in Young Finns Study (YFS) is a Finnish longitudinal population study on 
the evolution of cardiovascular risk factors from childhood to adulthood. These subjects for the baseline study in 
1980 were randomly selected from Finnish national registry from six different age groups between 3 to 18 years 
and five different study districts14. In the present study, we used the data from the follow-up in 2011, when 2,063 
subjects participated in blood sampling and in clinical examinations. Participants in the follow-up studies have 
been found to be more often women and older than those who dropped out, but no significant differences in risk 
factors have been found14. The present study has been approved by the Ethics Committee of the Hospital District 
of Southwest Finland on September 21st, 2010. The study protocol of each study phase corresponded to the pro-
posal by the World Health Organization. All subjects gave written informed consent and the study was conducted 
in accordance with the Helsinki declaration.
Clinical examinations. Waist and hip circumference, height and weight were measured and body mass 
index (BMI) calculated as kg/m². Blood pressure was measured as the average of three measurements taken at 
2-minute intervals in a sitting position from the right arm brachial artery by random zero sphygmomanometer. 
The metabolic syndrome was defined according to the harmonized definition15.
Data regarding daily alcohol consumption, physical activity, and smoking were obtained by questionnaires 
in 2011. Alcohol consumption data were acquired by standardized questionnaires and calculated in standard 
doses (12 g pure ethanol) per day by dividing the total number of doses consumed per week (0.33 L doses of beer 
or cider, 0.12 L doses of wine, and 0.04 L doses of hard liquor) by 7. Physical activity index was calculated (range 
5–15)16. The participants were classified as smokers if they smoked daily. Subjects were classified as diabetics 
based on questionnaires, blood fasting glucose and glycated hemoglobin measurements and national medica-
tion registry records. Complete information on history of HIV and hepatitis C were obtained from the Finnish 
National Hospital Discharge Register. None of the participants had a diagnosis of hepatitis C or HIV, which could 
potentially have contributed to the diagnosis of fatty liver.
Ultrasound imaging of liver. Ultrasound imaging of the liver was performed for 2,040 study participants 
using a validated protocol17 and Sequoia 512 ultrasound mainframes (Acuson, Mountain View, CA, USA) with 
4.0 MHz adult abdominal transducers. Evaluation of hepatic steatosis was performed according to liver-to-kidney 
contrast, parenchymal brightness, deep beam attenuation, and bright vessel walls18. According to these criteria 
the presence of hepatic steatosis was assessed visually from images by a highly trained ultrasonographer. The 
participants were classified into fatty liver (FL) and normal liver (NL) groups.
Blood samples and biochemistry. Venous blood samples were drawn from the right antecubital vein after 
an overnight fast and anticoagulated with EDTA. For liver enzyme quantification serum was separated, aliquoted, 
and stored at −70 °C until analysis. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
gamma-glutamyltransferase (GT) and triglyceride concentrations were measured by enzymatic methods (ALT, 
AST, GT and Triglycerides System Reagent, Beckman Coulter Biomedical, Ireland). Apolipoprotein B (ApoB) and 
C-reactive protein (CRP) were determined immunoturbidimetrically (ApoB assay reagent, Orion Diagnostica, 
Finland and CRP Latex reagent, Beckman Coulter Biomedical). The serum triglyceride concentration was assayed 
using the enzymatic glycerol kinase–glycerol phosphate oxidase method (Triglyceride reagent, Beckman Coulter 
Biomedical). All the above-mentioned assays were performed on an automatic analyzer (AU400, Olympus, 
Japan).
RNA isolation and quality control. Whole blood (2.5 ml) was collected into PaXgene Blood RNA Tubes 
(PreAnalytix). The tubes were inverted 8–10 times then stored at room temperature for at least 2 hours. The tubes 
were frozen (−80 °C) and thawed overnight before RNA isolation (both miRNA and total RNA) with a PAXgene 
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Blood microRNA Kit (Qiagen) including the DNase Set using the QiaCube (Qiagen). The concentrations and 
purity of the RNA samples were evaluated spectrophotometrically (BioPhotomer, Eppendorf). The RNA isola-
tion process was validated by analyzing the integrity of several RNAs (n = 26) with the RNA 6000 Nano Chip Kit 
(Agilent).
Genome wide expression analysis. 2,049 individuals gave blood samples to RNA isolation in the 30-year 
follow-up in 2011–2012. 63 samples were discarded during the RNA isolation protocol, leading to 1,987 samples 
including 1 technical replicate taking part in the genome wide expression analysis. 322 samples had too low 
concentration after amplification step. Finally, 1,667 samples were run with the expression BeadChip including 3 
technical replicates (2 from the mRNA amplification step).
The expression levels were analyzed with an Illumina HumanHT-12 version 4 Expression BeadChip (Illumina 
Inc.). In brief, 300–500 ng of RNA was reverse transcribed into cDNA and biotin-UTP labelled using the 
Illumina TotalPrep RNA Amplification Kit (Ambion), and 1,500 ng of cDNA was then hybridized to the Illumina 
HumanHT-12 v4 Expression BeadChip. The BeadChips were scanned with the Illumina iScan system.
Processing of GWE microarray data. Raw Illumina summary probe-level data was exported from Beadstudio 
and analyzed in R (http://www.r-project.org/) using the Bioconductor (http://www.bioconductor.org/) packages. 
The HT-12 v4 BeadChip contains 47,231 expression and 770 control probes. The transcripts detected (detection 
p-value < 0.01) in less than 5% of samples were excluded from the analysis. After this filtering 19,637 genes were 
used for analysis. We disregarded 4 samples with less than 6,000 significantly detected expression probes (detec-
tion p-value < 0.01). The expression data was processed using nonparametric background correction, followed by 
quantile normalization with control and expression probes, and log2 transformation using the neqc function in the 
limma package. Based on RPS4Y1–2 and XIST mRNA levels on the Y and X chromosomes, respectively, we excluded 
9 samples due to mismatch with the recorded sex. After quality control, expression data were available for 1,654 
samples including 4 technical replicates, which were used to examine batch effects and excluded subsequently. 1,650 
non-related samples were used for further analysis.
Definition of the cases and controls and statistical analysis for the demographics of the study 
population. Subjects were classified into two groups: FL (n = 316) and NL (n = 1,334) by a highly trained 
ultrasonographer and FL cases were considered as alcoholic fatty liver (AFL) (n = 55) if the daily alcohol con-
sumption exceeded 20 g for women and 30 g for men19. If the alcohol consumption was lower than these thresh-
olds, they were classified into non-alcoholic fatty liver (NAFL) group (n = 223). Demographics of the study 
participants were analyzed with R (version 3.2.2). These include all the parameters shown to be connected with 
fatty liver in a previous study of YFS participants including age, sex, BMI, alcohol consumption, smoking, systolic 
and diastolic blood pressure, waist to hip ratio, ApoB, triglycerides, insulin, liver enzymes (ALT, AST, GT) and 
physical activity index20. Data are presented as mean (SD). P values < 0.05 were considered significant. FL, NAFL 
and AFL groups were separately compared to control group using Mann-Whitney test for continuous parameters 
and χ2 test for classified parameters.
Gene set enrichment analysis (GSEA) of GWE data. The Canonical Pathways (CP) from the curated 
gene sets collection (C2) of the molecular signature database (MSigDB v5.0) database21 were used in gene set 
enrichment analysis (GSEA). Only pathways with 15 to 500 genes were included, resulting in using altogether 
870 pathways in the analysis. The alternative probes representing the same gene in the beadchip were collapsed to 
single genes by GSEA software, resulting in 14403 genes in the analysis.
GSEA software22,23 was used to analyze the association of gene pathways with the phenotype. A false dis-
covery rate (FDR) q-value < 0.25 can be considered as a significant according to the criteria recommended by 
Subramanian et al.22. However, we used a more stringent FDR q-value < 0.05 to select the statistically significant 
pathways. GSEA performs 1000 permutations when calculating the FDR values. Therefore, in the result tables we 
present p < 0.001 instead of 0 when the calculated FDR value appears as 0 in the GSEA results. R language (ver-
sion 3.2.2) was used for adjusting the gene expression data before the analysis with GSEA software. The expres-
sion levels were adjusted for sex and age (Model 1) and with those independent confounding factors previously 
associated with FL in our study sample (fully adjusted Model 2)20: adjusting the gene expression for age, sex, 
BMI, alcohol consumption, ApoB, triglycerides, insulin, systolic blood pressure, ALT, and physical activity index. 
In addition, to reduce the effect of technical factors24 we adjusted the expression levels for the first 20 principal 
components as described elsewhere25. Finally, inverse normal transformation was applied to the probes’ residual 
variance before analyzing them with the GSEA algorithm.
Similar analysis setup using the MSigDB canonical pathways were performed for all measurements: FL vs. NL, 
NAFL vs. NL and AFL vs. NL. In addition, GSEA was performed for NAFL vs. AFL to reveal the differences in 
gene expression pathways between these states.
Data Availability. The datasets analysed during the current study are not publicly available due to the reg-
ulations of Finnish law and the ethical permissions that prohibits uploading the YFS data to public platforms.
Results
General characteristics of the study sample. General demographics of the study population is pre-
sented in Table 1. Individuals with FL were more often men and older and were metabolically less healthy. They 
also had higher BMI and waist to hip ratio when compared to the NL group. 1.3% of the NL group had diabetes 
but for FL group the prevalence of diabetes was ten-fold (13.1%). Elevated systolic and diastolic blood pressure, 
ApoB, triglycerides, insulin, increased levels of liver enzymes (ALT, AST, GT) and CRP were also associated with 
FL. In addition, alcohol consumption and decreased physical activity were significantly related to FL. All the 
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mentioned characteristics differed significantly (P < 0.001) between the groups. Only exception to the previously 
identified risk factors20 was that daily smoking did not vary from the NL in the FL or NAFL groups in our study. 
However, smoking differed significantly (p = 0.022) between the subjects with AFL and NL. In addition, in the 
NAFL subgroup alcohol consumption was similar to the NL group. The subjects in the present study are rela-
tively young and include only 11 individuals with cardiovascular diseases including heart failure, coronary artery 
disease, coronary artery bypass grafting, coronary angioplasty, cerebrovascular disease and stroke. However, the 
number of subjects with cardiovascular diseases is insufficient to provide significant pathway enrichment results 
for this group.
Gene set enrichment analysis for FL. Fourteen gene sets were upregulated (FDR < 0.05) in subjects with 
FL (Table 2) in Model 1 (adjusting with sex, age, 20 principal components). These gene sets can be grouped into 
four groups describing the origin of the pathways: (1) pathways related to the extracellular matrix (ECM) turn-
over, (2) pathways regulating immuno-inflammatory response, (3) pathways contributing to thrombosis and (4) 
pathways related to neural tissues.
Pathways related to the extracellular matrix (ECM) turnover include two different integrin pathways (integrin 
A4B1 and integrin cell surface interactions), ECM receptor interaction and mCalpain pathway. All these gene sets 
share several integrin genes that mediate cell adhesion to ECM.
CD40/CD40L signaling pathway related to immune response was strongly enriched. Also, leukocyte 
transendothelial migration gene set associated to increased inflammation procedures in individuals with FL. 
Releated to these inflammation mechanisms, a pathway containing genes involved in signaling to extracellular 
signal-regulated kinases (ERKs) was also upregulated in FL group. Another upregulated pathway was HIVNEF, 
which promotes inflammation by helping CD4 helper T cells to prevent apoptosis.
Three upregulated pathways increase the probability for thrombosis in FL. They include integrin alphaIIB 
beta3 signaling, platelet aggregation plug formation and urokinase plasminogen activator (UPA) – UPA receptor 
(UPAR) pathway.
Interestingly, some of the upregulated pathways we identified in FL individuals have originally been identified 
from neural tissues. Netrin-1 signaling pathway, was initially linked to axon development and was recently also 
associated with atherosclerosis, controlling the trafficking of monocytes between blood and plaque26. Another 
upregulated gene set was Agrin in postsynaptic differentiation (AGR) pathway, which is related to neuromuscular 
junctions and organization of cytoskeleton in skeletal muscle. Alpha-synuclein signaling pathway, is previously 
identified from presynaptic neurons in human brain.
With fully adjusted Model 2, four gene sets remained significant (nominal p < 0.05) in FL group (Table 3). 
One of them was related with ECM turnover (integrin A4B1 signaling), two gene sets were related with immune 
NL FL NAFL AFL
Number of subjects in group 1,334 316 223 55
Age, years 41.55 (5.07) 43.16 (4.73) 42.91 (4.83) 44.47 (4.32)
Males (%) 534 (40.0) 221 (69.9) 151 (67.7) 42 (76.4)
Body mass index, kg/m2 25.60 (4.37) 30.75 (5.43) 30.99 (5.64) 30.01 (5.17)
Waist to hip ratio 0.88 (0.08) 0.98 (0.07) 0.98 (0.08) 0.99 (0.08)
Daily smokers (%) 172 (13.5) 48 (16.6) 34 (15.3) 14 (25.5)
Diabetics (%) 22 (1.7) 41 (13.1) 28 (12.7) 8 (14.5)
Metabolic syndrome (%) 167 (12.7) 183 (59.0) 130 (59.4) 33 (62.3)
Systolic BP, mmHg 117.38 (13.60) 128.22 (14.20) 126.89 (13.09) 132.61 (14.82)
Diastolic BP, mmHg 73.56 (9.86) 82.38 (10.64) 82.01 (10.61) 83.40 (10.89)
Apolipoprotein B, g/L 1.01 (0.26) 1.23 (0.33) 1.23 (0.33) 1.24 (0.31)
Triglycerides, mmol/L 1.15 (0.71) 2.04 (1.60) 2.07 (1.73) 1.96 (1.05)
Insulin, mU/L 8.11 (9.81) 17.70 (20.52) 17.81 (16.78) 14.69 (10.47)
ALT, U/L 14.40 (7.89) 26.91 (13.60) 26.57 (13.79) 30.16 (13.94)
AST, U/L 20.57 (5.43) 25.86 (6.99) 25.31 (6.99) 29.35 (7.03)
GT, U/L 24.90 (15.88) 46.66 (23.90) 45.29 (22.95) 58.03 (24.77)
CRP, mg/L 1.39 (2.14) 2.53 (3.24) 2.45 (3.09) 2.81 (3.78)
Alcohol consumption, drinks/day 0.71 (1.01) 1.25 (1.59) 0.65 (0.63) 3.70 (1.95)
Alcohol consumption, g/day 8.50 (12.16) 15.02 (19.13) 7.78 (7.53) 44.38 (23.42)
Physical activity index 9.20 (1.83) 8.40 (1.87) 8.50 (1.84) 8.06 (1.99)
Table 1. Summary of the 1,650 study participants: classified into normal liver and fatty liver groups of FL, 
NAFL and AFL. Values are mean (SD). Note: Alcohol consumption was available from 1,536 subjects. Statistics: 
Mann-Whitney test was used for continuous parameters and χ2 test for classified parameters when each fatty 
liver group was compared to controls (NL group). P < 0.001 for all other comparisons, except smoking (FL 
p = 0.209, NAFL p = 0.548 and AFL p = 0.022) and alcohol consumption (NAFL p = 0.192). Abbreviations: 
NL, normal liver; FL, Fatty liver; NAFL, non-alcoholic fatty liver; AFL, alcoholic fatty liver; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; GT, glutamyltransferase; CRP, C-reactive protein.
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response regulation (CD40/CD40L signaling pathway, leukocyte transendothelial migration) and one gene set 
associated with neuroimmune guidance cue 1 (netrin-1) signaling.
We also present the results of FL vs. NL comparisons for Model 1 in Supplementary Table 1 and for Model 2 in 
Supplementary Table 2 with cutoff value FDR < 0.25.
Gene set name SIZE ES NES
Nominal 
P value
FDR Q 
value
ECM turnover
  INTEGRIN_A4B1_PATHWAY 25 0.66 2.22 <0.001 0.003
  INTEGRIN_CELL_SURFACE_INTERACTIONS 47 0.61 2.22 <0.001 0.002
  ECM_RECEPTOR_INTERACTION 36 0.59 1.98 <0.001 0.031
  MCALPAIN_PATHWAY 17 0.69 2.02 <0.001 0.029
Immune response regulation
  CD40_PATHWAY 25 0.65 2.10 <0.001 0.010
  LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 75 0.51 2.04 <0.001 0.025
  SIGNALLING_TO_ERKS 28 0.57 1.93 <0.001 0.049
  HIVNEF_PATHWAY 54 0.49 1.93 0.002 0.046
Thrombosis
  INTEGRIN_ALPHAIIB_BETA3_SIGNALING 20 0.72 2.16 <0.001 0.004
  PLATELET_AGGREGATION_PLUG_FORMATION 25 0.75 2.26 <0.001 0.003
  UPA_UPAR_PATHWAY 23 0.65 2.00 0.004 0.035
Neural tissue
  NETRIN1_SIGNALING 20 0.64 2.02 <0.001 0.026
  AGR_PATHWAY 20 0.66 1.98 <0.001 0.034
  ALPHA_SYNUCLEIN_PATHWAY 26 0.57 1.89 0.004 0.049
Table 2. Gene sets upregulated in subjects with FL compared to NL using GSEA and adjusting for sex, age and 
20 principal components (Model 1). Gene sets with FDR < 0.05, no gene sets were enriched (FDR < 0.05) for 
downregulation in subjects with FL. Abbreviations: NL, normal liver; FL, fatty liver; GSEA, gene set enrichment 
analysis; ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.
Gene set name
FL (n = 316) NAFL (n = 223) AFL (n = 55)
M1 M2 M1 M2 M1 M2
ECM turnover
  INTEGRIN_A4B1_PATHWAY <0.001 0.013 <0.001 0.012 0.820 NA
  INTEGRIN_CELL_SURFACE_INTERACTIONS <0.001 0.289 <0.001 0.768 0.025 0.102
  ECM_RECEPTOR_INTERACTION <0.001 0.370 0.002 NA 0.132 0.674
  MCALPAIN_PATHWAY <0.001 0.076 0.004 0.089 0.168 0.542
Immune response regulation
  CD40_PATHWAY <0.001 <0.001 <0.001 <0.001 0.075 0.376
  LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION <0.001 0.023 0.016 0.092 0.203 0.369
  SIGNALLING_TO_ERKS <0.001 0.054 0.002 0.082 0.088 0.271
  HIVNEF_PATHWAY 0.002 0.080 0.004 0.215 0.042 0.191
Thrombosis
  INTEGRIN_ALPHAIIB_BETA3_SIGNALING <0.001 0.227 0.006 0.926 <0.001 0.119
  PLATELET_AGGREGATION_PLUG_FORMATION <0.001 0.185 0.004 0.898 <0.001 0.139
  UPA_UPAR_PATHWAY 0.004 0.107 0.006 0.098 0.017 0.307
Neural tissue
  NETRIN1_SIGNALING <0.001 0.018 <0.001 0.012 0.202 NA
  AGR_PATHWAY <0.001 0.110 <0.001 0.133 0.336 NA
  ALPHA_SYNUCLEIN_PATHWAY 0.004 0.479 <0.001 0.393 0.242 0.959
Table 3. Upregulated gene sets with different adjustment models for covariates. Values are shown as nominal 
p values for each gene set in the specified groups compared to normal liver group (n = 1334). Statistics: Model 
1 (M1) is adjusted for age, sex and 20 principal components; Model 2 (M2) is adjusted for age, sex, 20 principal 
components, body mass index, apolipoprotein B, triglycerides, insulin, systolic blood pressure, ALT, alcohol 
consumption and physical activity index. FL, Fatty liver; NAFL, non-alcoholic fatty liver; AFL, alcoholic fatty 
liver. NA means that the pathway was not upregulated in the specific group.
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Gene set enrichment analysis with fully adjusted model for NAFL and AFL. All the 14 gene sets 
upregulated in FL group with Model 1 were also significantly upregulated in NAFL group in comparison to con-
trols (nominal p < 0.05), using Model 1 adjustments. With Model 2 adjusting, we identified three upregulated 
gene sets: integrin A4B1 signaling, CD40/CD40L signaling pathway and netrin-1 signaling (Table 3).
However, the corresponding results for AFL in Model 1 analysis indicated five of the defined gene sets were 
significantly enriched for upregulation. They consist of integrin cell surface interactions, HIVNEF pathway and 
all three thrombosis related pathways (integrin alphaIIB beta3 signaling, platelet aggregation plug formation 
and UPA–UPAR pathway). For Model 2 analysis with AFL, none of the defined 14 gene sets was significantly 
upregulated.
When we compared the results of fully adjusted Model 2 with the Model 1, only a few gene sets remained 
statistically significantly upregulated for FL or NAFL. For example, all pathways related to thrombosis could be 
explained by the confounding factors. Three pathways were upregulated also in Model 2 analysis of FL and NAFL: 
integrin A4B1 signaling, CD40/CD40L signaling pathway and netrin-1 signaling pathway.
Discussion
This large study with 1,650 participants is to our knowledge the first wide-scale peripheral blood based GSEA 
analysis of subjects with FL. We hypothesized that hepatocellular accumulation of fatty acids and triglycerides 
trigger an inflammatory response in liver, which is visible via differential immuno-inflammatory gene pathway 
expression in blood. Furthermore, we investigated the effect of alcohol consumption history and fully adjusted 
model with previously known independent confounding factors to the observed gene pathways. After adjusting 
for the known confounding factors, we identified four activated pathways associated with FL, including integrin 
A4B1 signaling, leukocyte transendothelial migration (TEM), CD40/CD40L and netrin-1 signaling pathways.
These pathways are related to the following biological leukocyte functions: (a) their adherence to vessel wall, 
(b) transmigration, and/or (c) retaining in tissues. CD40/CD40L signaling pathway is suggested to increase 
adherence of CD40 positive cells, such as platelets and monocytes, to the vessel wall27. Integrin A4B1 (also 
known as very late antigen-4, VLA-4) signaling pathway is thought to be activated by chemotactic agents from 
injured cells28. Together integrin A4B1 (VLA-4) and leukocyte TEM pathways regulate the leukocyte migra-
tion from blood to organs through endothelium29,30. Netrin-1 signaling pathway increase leukocyte sensitivity to 
anti-inflammatory netrin-1, which is shown to decrease the accumulation of neutrophils but is downregulated in 
injured hepatic tissue31. As a consequence of these mechanisms, leukocytes increasingly transmigrate from blood 
and retain in injured liver tissue. Accumulated lymphocytes are known to induce fatty liver in different ways, 
such as by activating pro-inflammatory cytokines8. Furthermore, activated inflammatory mechanisms increase 
accumulation of lipids into liver, which then induce or exacerbate the progression of fatty liver. In mouse model 
of NASH, inflammatory cells also regulate hepatic lipase and lipoprotein lipase: CD8+ T cells, NKT cells and 
cytokines secreted by them induce liver damage, ultimately advancing towards hepatocellular carcinoma32. Our 
present findings would propose background mechanisms behind these previously known pathological changes 
in FL.
In the present study, upregulated CD40/CD40L signaling pathway was associated with FL, especially NAFL. 
Sookoian et al. found that circulating levels of soluble CD40 ligand (sCD40L) was significantly higher in 113 
NAFLD patients when compared to 102 control subjects33. This result is in line with our present findings. Previous 
results by Ercin et al. controversially indicated that sCD40L levels did not differ between 50 NAFLD subjects and 
30 healthy controls34. However, that evaluation was performed with smaller number of subjects than the previous 
and the present study. CD40L deficiency has been investigated in rodent models as well. Interestingly, Poggi et al. 
found that both the genetic CD40L deficiency and neutralizing anti-CD40L antibody therapy attenuated the 
development of FL and other metabolic disorders in mice35. Based on these previous studies and the present 
results we would suggest that C40/CD40L signaling pathway plays an important role in metabolic disorders such 
as FL. More specifically, CD40/CD40L signaling is suggested to increase adherence of CD40 positive cells, such as 
platelets and monocytes, to the vessel wall modulating atherothrombosis27.
Integrin A4B1 signaling pathway was significantly enriched in FL and NAFL groups. As previously indi-
cated, integrin A4B1 (VLA-4) is normally expressed on leukocyte plasma membranes. Activation of this antigen 
requires chemotactic agents from the site of injury i.e., endothelium or other cells. Endothelium expresses vas-
cular cell adhesion molecule-1 (VCAM-1) which binds to the VLA-4 and enables the transmission of leukocytes 
from blood to organs28. A4B1 has also been shown to bind osteopontin, while facilitating hepatic neutrophil 
infiltration and liver injury in the rat alcoholic steatohepatitis model36. Another significantly enriched pathway 
after adjusting for confounding factors was leukocyte transendothelial migration (TEM). That pathway is close to 
the VLA-4 pathway since they both regulate the migration of leukocytes from blood to tissue through endothe-
lium29,30. These gene sets correspond to the similar biological functionality but the TEM pathway reflects more 
biological functions by 75 genes (leukocyte – endothelium cell interactions) while integrin A4B1 signaling targets 
only 25 genes (leukocyte internal signaling). While Banerjee et al. associated leukocyte TEM functions with rat 
alcoholic steatohepatitis model36, we observed that the TEM pathways were activated in NAFL group. However, 
these pathways may reflect common pathogenic inflammatory mechanisms behind both AFLD and NAFLD8,9, 
and it is possible that the number of subjects with AFL (n = 55) is insufficient to reveal this change in the pres-
ent study. To determine if there exists difference in TEM pathways between NAFL and AFL in humans, further 
research is recommended with more subjects in the AFL group. To conclude, in the present study fatty liver is 
reflected to blood gene pathways in such way where specific factors (adherence and transmigration) driving leu-
kocytes to tissues are activated.
Neuroimmune guidance cue netrin-1 signaling pathway was upregulated in FL. Initially, netrins were con-
sidered as cell and axon guidance cue proteins in embryogenesis, and later identified outside the nervous sys-
tem influencing tissue morphogenesis37. Interestingly, in the present study netrin-1 gene was not differentially 
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expressed in our groups. Corresponding results have earlier been observed in another study, where expression of 
netrin-1 associated with atherosclerotic plaques, but did not differ in blood of patients with coronary artery dis-
ease compared with healthy controls26. Activated netrin-1 signaling pathway could indicate increased sensitivity 
of leukocytes and macrophages to the inflammatory mediators such as netrin-1. A recent study with mice sug-
gests netrin-1 as an anti-inflammatory factor in liver ischemia/reperfusion injury31, whereas our results extend 
that also into blood of patients with fatty liver. Netrin-1 is suggested to retain macrophages in atherosclerotic 
plaques26, and by the present results, we would suggest the corresponding effect in patients with FL.
To conclude, these pathways strongly suggest activation of immunological and inflammatory processes in 
blood of patients with fatty liver. A blood cascade including three different steps was identified with association of 
fatty liver. Firstly, adherence and transmigration of leukocytes from blood to tissues such as liver and vessel wall 
is activated. Secondly, interaction of monocytes and platelets is promoted which increases prothrombotic state. 
Thirdly, netrin-1 signaling pathway induces anti-inflammatory mechanisms by retaining leukocytes into tissues. 
However, in the present study setting we cannot determine the causality, whether the FL participates in produc-
tion of these inflammatory factors into blood or do the dysregulated gene pathways refer to systemic disturbances 
from which FL is one result. Therefore, we are unable to evaluate whether the activation of inflammation system 
in liver or blood is more important for FL. At least, our results may reflect common metabolic and inflammatory 
disturbances behind atherosclerosis and FL. Corresponding metabolic results have been identified in a study by 
Wree et al., where increased adipocyte size associated with elevated liver enzymes38. In addition, Kälsch et al. 
observed that in population based Heinz Nixdorf RECALL Study increasing liver enzymes (transaminases) even 
within normal ranges were significantly associated with metabolic changes, i.e., HbA1c, BMI and Type 2 diabe-
tes39. These observations support the present results of metabolic disturbances associated with FL. Interestingly, 
fatty liver status shared several pathways also associated with atherosclerosis or atherothrombosis (CD40/CD40L 
signaling pathway, Netrin-1 signaling and pathways contributing to thrombosis) i.e., another lipid related condi-
tion where lipids are accumulated to artery wall. Furthermore, recent research results would also suggest to link 
integrin A4B1 to atherosclerosis, where macrophages activate integrin A4B1 by expression of kindlin-340 in ather-
osclerotic plaques41. These shared pathways may form a common link between these two disease states where fatty 
liver is shown to increase the risk of cardiovascular diseases5. This suggestion is also supported by Baars et al., 
who found that elevated liver parameters are associated with stenosis diameter in acute myocardial infarction42.
Limitations and strengths of the study. A strength of the present study is that the subjects are based 
on the well-powered prospective randomly selected population based cohort, followed up for over 30 years with 
long well-known history of alcohol use and disease history. This study had large cohort (n = 1,650) and this adds 
the confidence to the present results. In addition, we used strict FDR limit in GSEA results and heavily adjusted 
our analysis with known fatty liver risk factors. The original suggestion was FDR < 0.25 but we used FDR < 0.05 
as a limit. The strict FDR limit combined to the large number of subjects and adjustment with known risk factors 
makes the results of this study reliable.
Limitations of the study include population homogeneity: all subjects are Finnish, ethnically homogenous 
Caucasian people. Because of that these results can be only generalizable in Caucasians. We unfortunately had 
no possibility for validation of the results in other comparable cohort. Therefore, we recommend the replication 
of our results and corresponding analysis for further research. In addition, majority of individuals with FL in 
our population are men. Even though sex has been included in statistical analyses as covariate and sex stratified 
analyses were performed, possible features specific for FL in women could have been missed due to low number 
of women with FL. The results cannot therefore be directly generalized to older populations with equal amounts 
of women and men with FL. The number of subjects in AFL group limited (n = 55), which is probably insufficient 
to reveal the alterations in the expression of gene pathways in this subgroup. Subjects with FL had more metabolic 
disorders, which may influence to the present results.
Furthermore, there is a risk of complications when the liver biopsy is taken and it is therefore unacceptable 
(unethical) to take liver biopsies from healthy asymptomatic individuals on population based studies. Analyzing 
blood samples is much safer and thus makes it possible to have much larger cohorts. Thus, we decided to analyze 
gene expression from blood tissue, which restricts the present observations to extrahepatic changes.
The key concept of analyzing gene sets instead of separate genes is considered as a strength of this study. The 
blood gene pathways reflect real metabolic and systemic functions. We were able to reveal much broader biolog-
ical mechanisms related to the FL using metabolic pathways instead of single genes.
In conclusion, FL was associated with blood gene sets of inflammatory response, immune system activation 
and prothrombotic state. These activated blood pathways may serve as a systemic link between FL and the devel-
opment of cardiovascular diseases.
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